Custom Header
search icon
menu icon
Gamma Delta T - cell Therapy
Gamma delta T - cell therapy is an advanced form of immunotherapy that utilizes gamma delta (γδ) T - cells, a specialized subset of T - cells with the unique ability to target and destroy cancer cells. 
Gamma Delta T - cell Therapy
Gamma delta T - cell therapy is an advanced form of immunotherapy that utilizes gamma delta (γδ) T - cells, a specialized subset of T - cells with the unique ability to target and destroy cancer cells. 

Gamma Delta T Cell Therapy

Gamma delta T cell therapy is an advanced form of immunotherapy that utilizes gamma delta (γδ) T cells, a specialized subset of T cells with the unique ability to target and destroy cancer cells. 

Book an Appointment

Our personalized treatment plans evolve with your cancer journey, ensuring that as your needs change, so does the level of care and support we provide. We are committed to empowering you to focus on your recovery, with treatment plans that adapt to meet your unique needs.

Tailored Assessments

Flexible Treatment Options

Personalized Care Planning

How does Gamma Delta T - cell Therapy work?

  1. Collection: T – cells are harvested from the healthy donor’s blood through a process known as leukapheresis.
  2. Activation and Expansion: The collected gamma delta T – cells are then activated and expanded in a laboratory setting to increase their number and efficacy.
  3. Infusion: The expanded gamma delta T – cells are infused back into the patient’s bloodstream.
  4. Targeting Cancer: These cells directly recognize and kill cancer cells while also stimulating other immune cells to attack the tumor, enhancing the overall immune response.

Healthy Donor

Blood Sample

Mononuclear cells

High-purity γ δ T cells

Many cancer patients

Tumor type

Ligands Identified

Acute Lymphoblastic Leukemia

28-67% MICA/B 9-20% ULBP1-3

Acute myeloid leukemia

0-75% MICA/B 16-50% ULBP1 4-64% ULBP2 16-100% ULBP3

Bladder carcinoma

70% MICA

Brain cancer

90% MICA/B and ULBP1-3

Breast cancer

35-100% MICA/B, ULBP1-5

Cervical cancer

20% MICA, ULBP2

Chronic lymphatic leukemia

0-85% MICA/B 10-20% ULBP1-3

Chronic myeloid leukemia

28-80% MICA/B 12-20% ULBP1-3

Colorectal cancer

80-100% MICA/B ULBP1-5

Tumor type

Ligands Identified

Hepatocellular carcinoma

60-100% MICA

Lymphoma

20-44% MICA/B 12-20% ULBP1-3

Melanoma

50% MICA/B

Multiple myeloma

10-60% MICA 0-34% ULBP1-3

Neuroblastoma

86% MICA/B, ULBP1-3

Non-small-cell lung cancer

20-30% MICA/B, ULBP1-3

Ovarian carcinoma

50-97% MICA/B, ULBP1-5

Pancreatic cancer

68-89.3% MICA/B

Prostate cancer

75-95% MICA/B, sMICA/B

Renal carcinoma

>95% MICA/B

Sarcoma​

100% MICA/B, ULBP1-3

Benefits

Broad Targeting:  Capable of recognizing and attacking a wide spectrum of cancer cells.

Low Risk of Graft-Versus-Host Disease (GVHD):  Reduced likelihood of GVHD compared to other T cell therapies.

Potential for Combination Therapy: Can be combined with other treatments to potentially enhance therapeutic outcomes.

Benefits

Broad Targeting: Capable of recognizing and attacking a wide spectrum of cancer cells.

Low Risk of Graft-Versus-Host Disease (GVHD): Reduced likelihood of GVHD compared to other T cell therapies.

Potential for Combination Therapy: Can be combined with other treatments to potentially enhance therapeutic outcomes.

Risks and Side-Effects

  • Cytokine Release Syndrome (CRS): May occur, leading to symptoms such as fever, fatigue, and low blood pressure.
  • Immune-Related Side Effects: Possible inflammation or autoimmune reactions.
  • Other Side Effects: May include infusion reactions, infections, and general fatigue.

How is Gamma Delta T - cell Therapy different from other T - cell therapies?

Gamma delta T – cells offer several unique features:

  • Recognition Mechanism: They target stress-induced molecules on cancer cells, allowing for broader targeting.
  • Reduced GVHD Risk: Lower incidence of GVHD compared to alpha beta T – cell therapies like CAR-T.
  • Immune Functions: They exhibit both innate and adaptive immune characteristics, providing a versatile approach to treatment.

Eligibility Factors

Eligibility depends on factors such as:

  • Type and Stage of Disease
  • Overall health and medical history

A thorough evaluation by a healthcare team is essential to determine if Gamma delta T – cell therapy is a suitable option.

Success Rate

Success rates can vary based on the cancer type and individual patient factors. Clinical trials are ongoing to better understand its effectiveness and long-term benefits. Early results have shown promising potential for significant anti-tumor activity.

During Therapy

The infusion process is typically performed on an outpatient basis, but patients require close monitoring for potential adverse reactions.

After Therapy

Regular follow-up visits are crucial to monitor for side effects and evaluate treatment effectiveness.

Recovery

Side effects may include fatigue, fever, and other immune-related reactions.

Process

Insurance Coverage

Insurance coverage varies by provider and plan. It is advisable for patients to consult with their healthcare provider and insurance company to understand coverage options and potential costs.

Next steps if Gamma Delta T - cell Therapy doesn’t work

If Gamma delta T – cell therapy is not effective, alternative options may include

  • Other immunotherapies
  • Targeted therapies
  • Participation in additional clinical trials
  • Supportive care to manage symptoms and improve quality of life.

Contact Us

Have questions or need support? We’re here for you. Connect with us today, and let’s work together on a path toward healing and well-being

Contact Information

Fill in the required details and our team will get back to you

  • contact@sunactcancer.com
  • SunAct Cancer Institute Pvt. Ltd. 4th floor,
Tieten Medicity Hospital,
Kasarvadavali, Ghodbunder Road,
Thane (West) - 400615. Maharashtra, India
    Map: View Location Arrow Icon
  • Phone
    +9186553 13412
  • Toll free
    18002022232

Book an Appointment

Take the first step toward healing with expert cancer care.